PRTN3 and inflammatory bowel disease: Twenty-five of the 249 samples tested positive for PR3-ANCA (10.0% [64% with reactivity above 37 units]), and it was more frequently detected in PSC/IBD+ than in PSC/IBD- patients (p=0.025).